USPTO Art Unit 1644 Prosecution Statistics

Art Unit Information

Art Unit: 1644
Group: 1640
Tech Center: 1600
Total Cases: 15,730
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19043567HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOFFebruary 2025June 2025Allow400YesNo
18999710ANTI-FUNGAL VHH ANTIBODIESDecember 2024May 2025Allow410NoNo
18984595PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPYDecember 2024July 2025Allow620NoNo
18910549Humanized Anti-DNAM-1 AntibodyOctober 2024March 2025Abandon1010NoNo
18910550ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOFOctober 2024March 2025Allow610NoNo
18906588TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEMOctober 2024April 2025Allow610NoNo
18883719COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINSSeptember 2024January 2025Allow410YesNo
18747102MULTIVALENT AND BISPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOFJune 2024March 2025Allow911YesNo
18742215METHOD FOR MAKING PLURIPOTENT STEM CELLSJune 2024September 2024Allow300NoNo
18732517Reducing side effects of immunotherapy using genetically modified hematopoietic cellsJune 2024February 2025Allow811YesNo
18731180CELL SIGNALING COMPLEXES AND USES THEREOFMay 2024December 2024Allow711YesNo
18667995CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMAMay 2024March 2025Allow1000NoNo
18664078BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024April 2025Allow1120YesNo
18658896CEACAM5-DEPENDENT 4-1BB-AGONISTIC BISPECIFIC ANTIBODIESMay 2024November 2024Allow610NoNo
18658421OX40-Binding Polypeptides and Uses ThereofMay 2024February 2025Allow900NoNo
18651979ANTI-AGING SALMON ROE TRIPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOFMay 2024February 2025Allow1020NoNo
18649790Adenoviral Vector Transduced Apheresis ProductApril 2024January 2025Allow921YesNo
18638307COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERSApril 2024June 2024Allow200YesNo
18623883NUCLEASES AND COMPOSITIONS, SYSTEMS, AND METHODS THEREOFApril 2024August 2024Allow410NoNo
18612088ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOFMarch 2024September 2024Allow610YesNo
18612866ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOFMarch 2024September 2024Allow610YesNo
18605049MRNA THERAPEUTIC COMPOSITIONSMarch 2024August 2024Allow510YesNo
18690247ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOFMarch 2024May 2025Allow1401NoNo
18589536PD-1 Single Domain Antibodies and Therapeutic Compositions ThereofFebruary 2024January 2025Allow1100YesNo
18440860ANTI-CD28 X ANTI-PSMA ANTIBODIESFebruary 2024April 2025Allow1421NoNo
18429213Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigensJanuary 2024June 2025Allow1600YesNo
18426912FUSION PROTEIN AND NUCLEIC ACID ENCODING SEQUENCE THEREOF, AND USES OF THE SAMEJanuary 2024November 2024Allow1020YesNo
18420296ANTI-NGF ANTIBODIES AND USES THEREOFJanuary 2024March 2025Allow1421YesNo
18418078Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigenJanuary 2024December 2024Allow1111NoNo
18389914ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTSDecember 2023March 2025Allow1501YesNo
18543673CD28/OX40 BISPECIFIC ANTIBODIESDecember 2023May 2024Allow501YesNo
18510256Anti-cMet Antibody-Drug Conjugates and Uses ThereofNovember 2023May 2025Allow1841YesNo
18508938CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOFNovember 2023June 2025Allow1910NoNo
18508501PD1 BINDING AGENTSNovember 2023February 2025Abandon1510YesNo
18505881MRNA THERAPEUTIC COMPOSITIONSNovember 2023February 2024Allow300YesNo
18501581DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow200NoNo
18501584DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow300NoNo
18501850DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow300NoNo
18501914DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023May 2024Allow710NoNo
18501561DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow200NoNo
18501884DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow400NoNo
18501762DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023December 2023Allow200NoNo
18501571DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023August 2024Allow920NoNo
18501856DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow300NoNo
18497745METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPYOctober 2023May 2025Allow1810NoNo
18495541COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGSOctober 2023May 2025Abandon1801NoNo
18492221T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSOctober 2023September 2024Allow1120YesNo
18492310T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSOctober 2023December 2024Abandon1320YesNo
18490445MAJOR HISTOCOMPATIBILITY COMPLEX-BASED CHIMERIC RECEPTORS AND USES THEREOF FOR TREATING AUTOIMMUNE DISEASESOctober 2023May 2025Allow1911YesNo
18486678COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONSOctober 2023April 2025Abandon1802NoNo
18485680CD3-DELTA/EPSILON HETERODIMER SPECIFIC ANTIBODIESOctober 2023April 2025Abandon1810NoNo
18485163ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USEOctober 2023June 2024Allow800NoNo
18480825HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS OF TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROMEOctober 2023December 2024Abandon1510NoNo
18473002ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1September 2023September 2024Allow1210NoNo
18466354GENETICALLY ENGINEERED GAMMA DELTA T CELLSeptember 2023July 2025Abandon2211NoNo
18457778DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSISAugust 2023November 2024Allow1511YesNo
18451514METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSISAugust 2023February 2025Abandon1801NoNo
18450234Methods to Expand a T Regulatory Cell Master Cell BankAugust 2023June 2025Abandon2220NoNo
18448870ANTI-PVRIG ANTIBODIES AND METHODS OF USEAugust 2023January 2025Allow1720NoNo
18365828HER2 TARGETING AGENTAugust 2023March 2024Allow710NoNo
18230449SYSTEM AND METHOD OF PREPARING AND STORING ACTIVATED MATURE DENDRITIC CELLSAugust 2023April 2025Abandon2111NoNo
18364644THERAPEUTIC AGENT TARGETED TO RECEPTOR PROTEIN, TEST AGENT, ANTIBODY THAT BINDS TO RECEPTOR PROTEIN, AND SCREENING METHOD FOR MOLECULARLY TARGETED DRUGSAugust 2023June 2024Allow1010NoNo
18363672T CELL RECEPTORSAugust 2023August 2024Allow1310NoNo
18358659GENETICALLY MODIFIED STEM CELLSJuly 2023May 2025Allow2110NoNo
18358833METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONSJuly 2023January 2024Allow610YesNo
18354395Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)July 2023April 2025Abandon2121NoNo
18218943MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOFJuly 2023February 2024Allow821YesNo
18348173ANTI-NGF ANTIBODIES AND USES THEREOFJuly 2023May 2024Allow1011NoNo
18345885CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOFJune 2023September 2024Allow1411NoNo
18346130CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETINGJune 2023June 2024Allow1110NoNo
18342897IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATIONJune 2023May 2025Abandon2201NoNo
18340600T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOFJune 2023April 2025Allow2210NoNo
18340242SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOFJune 2023December 2024Allow1821NoNo
18339663T CELL RECEPTORSJune 2023August 2024Allow1410YesNo
18339197IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOFJune 2023March 2025Allow2121NoNo
18333753COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYJune 2023November 2024Allow1701YesNo
18333096HLA-DR CAR-T COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMEJune 2023May 2025Abandon2310NoNo
18206552T CELL REGULATIONJune 2023March 2025Abandon2101NoNo
18327127ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERSJune 2023December 2023Allow720NoNo
18324915Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activityMay 2023September 2024Allow1621NoNo
18318610BISPECIFIC ANTIBODYMay 2023December 2023Allow711YesNo
18317199COMPOSITION FOR CULTURING REGULATORY T CELLS AND USE THEREOFMay 2023October 2024Abandon1701NoNo
18316198MODIFIED B CELLS AND METHODS OF USE THEREOFMay 2023March 2024Allow1021NoNo
18315782USING REPROGRAMMED, PERSONALIZED CANCER STEM CELLS AS A TRIPLE-KILLER CANCER TREATMENTMay 2023February 2025Abandon2121NoNo
18142242NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATIONMay 2023July 2023Allow300NoNo
18310120METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPYMay 2023January 2025Allow2111YesNo
18309272Anti-ULBP6 AntibodiesApril 2023April 2024Allow1200YesNo
18298263INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPYApril 2023October 2024Allow1810NoNo
18298129CELLULAR POPULATIONS AND USES THEREOFApril 2023October 2024Abandon1810NoNo
18296345ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTIONApril 2023January 2024Abandon900NoNo
18295965MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLSApril 2023October 2024Allow1911NoNo
18194105Anti-Coronavirus Antibodies and Methods of UseMarch 2023August 2024Allow1610YesNo
18190954T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOFMarch 2023November 2024Abandon1910NoNo
18188318T CELL-ANTIGEN COUPLER WITH Y182T MUTATION AND METHODS OF USES THEREOFMarch 2023December 2023Allow910NoNo
18186730Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered formMarch 2023September 2023Allow601YesNo
17915109MONOCLONAL ANTIBODY BINDING TO TIGIT ANTIGEN, PREPARATION METHOD AND USE THEREOFMarch 2023September 2023Allow1210NoNo
18023701ANTI-VEGF-ANTI-PD-L1 BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION OF SAME, AND USES THEREOFFebruary 2023April 2025Allow2510NoNo
18113413IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOFFebruary 2023April 2025Allow2610YesNo
18172773ANTI-P53 ANTIBODIESFebruary 2023August 2024Allow1820NoNo
18111179ANTI-PAD2 ANTIBODY FOR TREATING AND EVALUATING AUTOIMMUNE AND INFLAMMATORY DISEASESFebruary 2023March 2025Allow2521NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1644.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
295
Examiner Affirmed
223
(75.6%)
Examiner Reversed
72
(24.4%)
Reversal Percentile
13.6%
Lower than average

What This Means

With a 24.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
2003
Allowed After Appeal Filing
261
(13.0%)
Not Allowed After Appeal Filing
1742
(87.0%)
Filing Benefit Percentile
0.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1644 - Prosecution Statistics Summary

Executive Summary

Art Unit 1644 is part of Group 1640 in Technology Center 1600. This art unit has examined 15,730 patent applications in our dataset, with an overall allowance rate of 48.2%. Applications typically reach final disposition in approximately 36 months.

Comparative Analysis

Art Unit 1644's allowance rate of 48.2% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1644 receive an average of 1.91 office actions before reaching final disposition (in the 58% percentile). The median prosecution time is 36 months (in the 16% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.